Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Brief Summary: The primary objective of this study is to evaluate the efficacy of ibrutinib in combination with obinutuzumab compared to chlorambucil in combination with obinutuzumab based on the Independent Review Committee (IRC) assessment of progression free survival (PFS). Efficacy will be evaluated according to 2008 International Workshop for Chronic Lymphocytic Leukemia (IWCLL) criteria with the modification for treatment-related lymphocytosis, in subjects with treatment-naive CLL or SLL.


Options:
A: Arm Label: IBR + OB; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Drug: Obinutuzumab | Arm Label: CLB + OB; Type: EXPERIMENTAL; Interventions: Drug: Obinutuzumab, Drug: Chlorambucil | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): IBR + OB | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): CLB + OB, IBR + OB | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): CLB + OB
B: Arm Label: Arm A (ibrutinib, rituximab); Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Other: Laboratory Biomarker Analysis, Other: Pharmacogenomic Study, Other: Quality-of-Life Assessment, Biological: Rituximab | Arm Label: Arm B (rituximab, fludarabine phosphate, cyclophosphamide); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate, Other: Laboratory Biomarker Analysis, Other: Pharmacogenomic Study, Other: Quality-of-Life Assessment, Biological: Rituximab | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Arm A (ibrutinib, rituximab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: OTHER; Name: Pharmacogenomic Study; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide)
C: Arm Label: Arm A - Obinutuzumab in Combination with Chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Obinutuzumab, Drug: Chlorambucil | Arm Label: Arm B - Acalabrutinib in Combination with Obinutuzumab; Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib, Drug: Obinutuzumab | Arm Label: Arm C - Acalabrutinib Monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib | Intervention Type: DRUG; Name: Acalabrutinib; Assigned to Arm(s): Arm B - Acalabrutinib in Combination with Obinutuzumab, Arm C - Acalabrutinib Monotherapy | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Arm A - Obinutuzumab in Combination with Chlorambucil, Arm B - Acalabrutinib in Combination with Obinutuzumab | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Arm A - Obinutuzumab in Combination with Chlorambucil
D: Arm Label: Cohort 1: Bendamustine + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Cohort 1: Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 1a (China only): Bendamustine + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Cohort 1a (China only): Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 2: Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 3: Venetoclax + Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib, Drug: Venetoclax | Intervention Type: DRUG; Name: Zanubrutinib; Assigned to Arm(s): Cohort 1: Zanubrutinib, Cohort 1a (China only): Zanubrutinib, Cohort 2: Zanubrutinib, Cohort 3: Venetoclax + Zanubrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Cohort 1: Bendamustine + Rituximab, Cohort 1a (China only): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Cohort 1: Bendamustine + Rituximab, Cohort 1a (China only): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Cohort 3: Venetoclax + Zanubrutinib

Answer: A